Sarepta Eteplirsen merits accelerated approval, says Piper Jaffray

After viewing a presentation by Sarepta CEO Chris Garabedian, Piper Jaffray believes that the company's Eteplirsen for Duchenne's muscular dystrophy generated "remarkable" data in a Phase IIb study. The firm thinks that eteplirsen meets the criteria for accelerated approval, and it maintains an Overweight rating on the stock.

View Comments (0)